NCT04195633View on ClinicalTrials.gov

Donor Stem Cell Transplant With Treosulfan, Fludarabine, and Total-Body Irradiation for the Treatment of Hematological Malignancies

PHASE2RecruitingINTERVENTIONAL
Enrollment

60

Participants

Timeline

Start Date

January 25, 2021

Primary Completion Date

February 19, 2026

Study Completion Date

January 10, 2028

Conditions
Acute LeukemiaAcute Lymphoblastic LeukemiaAcute Myeloid LeukemiaAdult Diffuse Large Cell LymphomaAnaplastic Large Cell LymphomaBurkitt LymphomaChronic Myeloid Leukemia, BCR-ABL1 PositiveChronic Myelomonocytic LeukemiaHodgkin LymphomaLymphoblastic LymphomaLymphoplasmacytic LymphomaMantle Cell LymphomaMixed Phenotype Acute LeukemiaMyelodysplastic SyndromeProlymphocytic LeukemiaRefractory Chronic Lymphocytic LeukemiaRefractory Follicular LymphomaRefractory Marginal Zone LymphomaRefractory Small Lymphocytic Lymphoma
Interventions
PROCEDURE

Allogeneic Hematopoietic Stem Cell Transplantation

Undergo allogeneic hematopoietic stem cell transplantation

DRUG

Cyclophosphamide

Given IV

DRUG

Cyclosporine

Given IV or PO

BIOLOGICAL

Filgrastim

Given IV

DRUG

Fludarabine

Given IV

DRUG

Mycophenolate Mofetil

Given IV or PO

DRUG

Mycophenolate Sodium

Given PO

RADIATION

Total-Body Irradiation

Undergo total-body irradiation

DRUG

Treosulfan

Given IV

PROCEDURE

Bone Marrow Aspiration

Undergo bone marrow aspiration

PROCEDURE

Bone Marrow Biopsy

Undergo bone marrow biopsy

PROCEDURE

Echocardiography

Undergo echocardiography

PROCEDURE

Biospecimen Collection

Undergo blood sample collection

PROCEDURE

Computed Tomography

Undergo CT or PET/CT

PROCEDURE

Positron Emission Tomography

Undergo PET/CT

Trial Locations (1)

98109

RECRUITING

Fred Hutch/University of Washington Cancer Consortium, Seattle

All Listed Sponsors
collaborator

medac GmbH

INDUSTRY

lead

Fred Hutchinson Cancer Center

OTHER